Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: A retrospective monocentre study on 547 patients

Clinical Microbiology and Infection

Volumn 20, Issue 2, 2014, Pages 160-166

  Venton, G ^a   Crocchiolo, R ^a   Furst S ^a   Granata, A ^a   Oudin, C ^a   Faucher, C ^a   Coso, D ^a   Bouabdallah, R ^a   Berger, P ^a   Vey, N ^a   Ladaique, P ^a   Chabannon, C ^a   le Merlin, M ^b   Blaise, D ^a   El Cheikh, J ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b Laboratoire PC Bio   (France)

Author keywords

Allogeneic stem cell transplantation; Cytomegalovirus; Gancyclovir; Neutropenia

Indexed keywords

AMOXICILLIN; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN A; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALACICLOVIR;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TOXOPLASMOSIS; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REACTIVATION; YOUNG ADULT;

BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS;

ALLOGENEIC STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; GANCYCLOVIR; NEUTROPENIA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84892480241     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12222     Document Type: Article

References (27)

1. Bacigalupo A, Tedone E, Sanna MA et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Haematologica 1992; 77: 507-513.
2. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008.
3. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42 (Suppl 1): S70-S72.
4. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011; 25: 151-169.
5. Ruiz-Camps I, Len O, de la Camara R et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Antivir Ther 2011; 16: 951-957.
6. Liu KY, Wang Y, Han MZ et al. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial. Chin Med J (Engl) 2010; 123: 2199-2205.
7. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997; 90: 2502-2508.
8. Tomonari A, Iseki T, Takahashi S et al. Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation. Ann Hematol 2004; 83: 573-577.
9. Blaise D, Farnault L, Faucher C et al. Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Exp Hematol 2010; 38: 1241-1250.
10. Chakrabarti S. Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty. Blood 2003; 101: 2071.
11. Bacigalupo A, Ballen K, Rizzo D et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
12. Devillier R, Crocchiolo R, Castagna L et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 639-645.
13. Nakamae H, Storer B, Sandmaier BM et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011; 96: 1838-1845.
14. Ozdemir E, Saliba RM, Champlin RE et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 40: 125-136.
15. Hagglund H, Bostrom L, Remberger M, Ljungman P, Nilsson B, Ringden O. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747-753.
16. Bjorklund A, Aschan J, Labopin M et al. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 40: 1055-1062.
17. Ljungman P, Oberg G, Aschan J et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 18: 565-568.
18. Zaia JA, Sissons JG, Riddell S et al. Status of Cytomegalovirus Prevention and Treatment in 2000. Hematology Am Soc Hematol Educ Program 2000: 339-355.
19. Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002; 35: 999-1004.
20. Broers AE, van Der HR, van Esser JW et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240-2245.
21. Kanda Y, Mineishi S, Saito T et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-444.
22. Meijer E, Dekker AW, Rozenberg-Arska M, Weersink AJ, Verdonck LF. Influence of cytomegalovirus seropositivity on outcome after T-cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis 2002; 35: 703-712.
23. Pietersma FL, van Dorp S, Minnema MC et al. Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients. Clin Infect Dis 2011; 52: e144-e148.
24. George B, Pati N, Gilroy N et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010; 12: 322-329.
25. Green ML, Leisenring W, Stachel D et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation 5. Biol Blood Marrow Transplant 2012; 18: 1687-1699.
26. Boeckh M, Zaia JA, Jung D, Skettino S, Chauncey TR, Bowden RA. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 13-19.
27. Zaia JA, Schmidt GM, Chao NJ et al. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. Biol Blood Marrow Transplant 1995; 1: 88-93.